The interleukin-10 gene promoter polymorphism −1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma

被引：0
作者：
D Kube
T-D Hua
M Klöss
B Kulle
J Brockmöller
L Wojnowski
M Löffler
M Pfreundschuh
L Trümper
机构：
[1] Universitätsmedizin der Georg-August-Universität,Department of Hematology and Oncology
[2] Institute of Medical Informatics,Department of Statistics and Epidemiology
[3] University of Leipzig,Department of Pharmacology and Toxicology
[4] Institute of Epidemiology,Department of Internal Medicine I
[5] Universitätsmedizin der Georg-August-Universität,undefined
[6] Section of Statistics,undefined
[7] Institute of Basic Medical Science,undefined
[8] University of Oslo,undefined
[9] Universitätsmedizin der Georg-August-Universität,undefined
[10] Institute of Pharmacology,undefined
[11] University Mainz,undefined
[12] Saarland University,undefined
[13] Homburg/Saar for the DSHNHL (German High Grade NHL study group),undefined
来源：
Genes & Immunity | 2007年 / 8卷
关键词：
IL-10; polymorphisms; non-Hodgkin's lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The Interleukin 10 (IL-10) gene is highly polymorphic, and the IL-10−1087AG (rs1800896) gene variation is the only so far studied intensively in association with certain diseases. Conflicting data have been published about an association of IL-10−1087AG gene variation with lower rates of complete remission and lower overall survival (OS) in patients with diffuse large B-cell lymphoma. To further investigate this in malignant lymphoma, we established the IL-10 genotypes in patients from the NHL-B1/ B2 studies from the German High-Grade Non-Hodgkin's Lymphoma Study Group. In our study, allele frequencies of lymphoma patients are comparable as in healthy controls. No increase of IL-10–1087G alleles was found. In addition we did not find any difference in OS or event-free survival between patients with IL-10–1087AA and the other genotypes. Comparable results were obtained for the IL-10 loci at −3538 (A/T), −1354 (A/G), −824 (C/T) and −597 (A/C) (rs1800890, rs1800893, rs1800871 and rs1800872).
引用
收藏
页码：164 / 167
页数：3
相关论文
共 104 条
[21]  
DeVita S(2004)Mosaics of gene variations in the Interleukin-10 gene promoter affect interleukin-10 production depending on the stimulation used Genes Immun 5 246-255
[22]  
Ho M(2004)Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma Blood 103 3529-3534
[23]  
Schollaardt T(2005)The interleukin-10 gene promoter polymorphism (−1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma Blood 105 4894-4895
[24]  
Snape S(2006)Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium Lancet Oncol 7 27-38
[25]  
Sarris AH(2006)Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk Genes Immun 7 615-624
[26]  
Kliche KO(2004)Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL Blood 104 634-641
[27]  
Pethambaram P(2004)Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL Blood 104 626-633
[28]  
Goldman M(2005)NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity Circulation 112 3754-3762
[29]  
Velu T(2004)Chromatin-level regulation of the IL10 gene in T cells J Biol Chem 279 46818-46825
[30]  
Pretolani M(2006)Dynamic and transient remodeling of the macrophage IL-10 promoter during transcription J Immunol 177 1282-1288
12345678910